logo
Plus   Neg
Share
Email

TJX Companies Boosts FY20 Outlook As Q1 Results Top Estimates - Quick Facts

Off-price retailer TJX Companies, Inc. (TJX) reported Tuesday a decline in profit for the first quarter from last year. However, both earnings per share and sales for the quarter topped analysts' expectations. The company also raised its earnings outlook for the full year 2020.

TJX's first-quarter net income decreased to $700.18 million or $0.57 per share from $716.38 million or $0.56 per share in the prior-year quarter.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.55 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter increased 7 percent to $9.28 billion from $8.69 billion in the same quarter last year and beat analysts' consensus revenue estimate of $9.21 billion.

Consolidated comparable store sales rose 5 percent, compared to an increase of 3 percent in the same period last year. Customer traffic was once again the primary driver of comparable store sales increases at each of the company's four large divisions.

Looking ahead to the second quarter, TJX Companies forecast earnings in a range of $0.61 to $0.62 per share, based upon estimated comparable store sales growth of 2 to 3 percent on a consolidated basis and at Marmaxx. Analysts expect earnings of $0.62 per share.

For fiscal 2020, TJX Companies now projects earnings in a range of $2.56 to $2.61 per share, based upon estimated consolidated comparable store sales growth of 2 to 3 percent on a consolidated basis and at Marmaxx. The Street expects earnings of $2.61 per share for the year.

Earlier, the company forecast earnings in the range of $2.55 to $2.60 per share, based upon estimated consolidated comparable store sales growth of 2 to 3 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration or FDA announced on its website that pharma major Pfizer, Inc. issued recall of two lots of tablets meant to treat acute migraine in adults for concerns over bacteria infection. The pharma company is recalling two lots of Relpax (eletriptan hydrobromide) 40 mg tablets for potential presence of Genus Pseudomonas and Burkholderia bacteria. Cosmetics company Revlon Inc. (REV) is reportedly considering a potential sale of parts or all of its business. According to Bloomberg, Revlon has retained financial advisers from Goldman Sachs Group Inc. to explore strategic alternatives. No deal has been reached yet, but Revlon is exploring all... China's Lenovo Group Ltd. warned it may have to raise prices of its products if the U.S. moves ahead with the decision to impose additional tariffs on Chinese goods, according to a report by Reuters. The warning by Lenovo, the world's largest PC maker, comes amid the escalating trade war between the U.S. and China that has raised concerns about the global economic outlook.
Follow RTT